For all the breathless hype and attention focused on antibody-drug conjugates (ADCs) of late, you might…
Part 2 of our WCLC 2023 Previews
Bispecifics come and bispecifics go as companies seek to find a balance
What really stood out from the oral presentations at ESMO this year?
An in-depth look at some of the issues impacting Amgen's pivotal trial and what it means for their competitors
How do we help more early stage ccRCC patients live long and prosper?
Round up ad discussion of key breast cancer trials in HR+/HER2- disease
Are all PARP inhibitors the same?
New developments in early stage targeted therapy agents
In our latest ESMO conference preview it’s time to pick some early stage immunotherapy highlights…
What to watch out for in colorectal cancer, cholangiocarcinoma and hepatocellular carcinoma
Review of some of the key trials in breast cancer being showcased in Paris next month
